| Autor: |
Abhishek, Nyati, Archana, Gokhroo, Gaurav, Sharma |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
The Journal of the Association of Physicians of India. 70(4) |
| ISSN: |
0004-5772 |
| Popis: |
The coronavirus disease 2019 (COVID-19) virus has spread all over the world. Scientists are trying to discover drugs as effective treatment for patients with COVID-19. So far about 30 drugs have been introduced that one of them is Tocilizumab. Some reports showed a positive effect of Tocilizumab on Saturation of Peripheral Oxygen (SPO2) but results of CT scan in patients in different. In some patients, CT scan showed reduced infiltration, however in other no change was observed. Unfortunately, until now there has been no definitive and effective treatment for patients with COVID-19. Based on evidence of the Tocilizumab's effect on the SARS COV 2, researchers hope this drug will make effective and promising treatment to improve lung tissue inflammation in patients with the fatal COVID-19 virus. The present study provides an overview of respiratory inflammation with COVID-19 and probable effect of Tocilizumab on SARS-COV 2.A Case Series was conducted on 30 patients, RT-PCR confirmed COVID-19 cases; admitted and kept under observation in medicine ward, ICU or dedicated COVID-19 wards of RNT Medical College and associated group of Hospitals for a duration of 30 days after getting approval from institutional ethics committee if they met inclusion and exclusion criteria. Data was collected from records at the time of admission of these cases.In our study on day 1 mean of IL6 was 248.3 and on day 3 after giving injection Tocilizumab mean of IL6 was 138.7 and p value was 0.205 and on day1 mean of serum ferritin was 474.2 and on day 3 after giving injection Tocilizumab mean of serum ferritin was 415.2 and p value was 0.649 and on day 1 mean of LDH was 652 and on day 3 after giving injection Tocilizumab mean of LDH was 389.6 and p value was 0.006 and on day 1 mean of CRP was 100 and on day 3 after giving injection Tocilizumab mean of CRP was 35.95 and p value was 0.006 and out of 30 patient 22 patients were discharged and 8 patients declared death.In present study it was interpreted that injection Tocilizumab play an important role in reducing inflammation in COVID 19disease. Tocilizumab have significant role in reducing mortality from COVID 19. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
